MIPS research licensed
Technology based on Monash University research licensed by PureTech Health to Boehringer Ingelheim
Technology developed at MIPS and recently licensed to PureTech Health (PRTC) will be researched in collaboration with Boehringer Ingelheim to develop novel immuno-oncology product candidates. The lymphatic targeting technology is based on the research of Professor Chris Porter and Dr Natalie Trevaskis and their team at MIPS.
The collaboration will employ the proprietary lymphatic targeting platform that PRTC licensed from Monash University, and is now developing through its internal R&D division.
The approach harnesses the gut’s lipid transport mechanisms to enable oral administration and transport of drug candidates directly through the gut-draining lymphatic vasculature, also bypassing first pass metabolism in the liver. By targeting the lymphatic system directly, the technology has the potential to achieve more effective and precise immunomodulation of local tissues, while sparing the patient adverse effects of extensive systemic exposure.
Under the terms of the agreement, PRTC will receive up to $26 million, including upfront payments, research support, and preclinical milestones, and is eligible to receive more than $200 million in development and sales milestones, in addition to royalties on product sales, whilst MIPS will receive a specified revenue stream.
“This collaboration signals the exciting potential of another proprietary platform from our internal R&D to enable novel immunotherapy approaches,” said Daphne Zohar, co-founder and CEO of PRTC. “We’re pleased to continue our collaboration with MIPS as we advance this technology platform from the laboratory to the clinic.”